Bristol-Myers Squibb
More from Xconomy.com:
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
There is an exit payment for Exelixis.
Bristol-Myers Squibb
More from Xconomy.com:
Exelixis is a Motley Fool Rule Breakers recommendation.
Luke Timmerman is the National Biotechnology Editor for Xconomy, and the Editor of Xconomy Seattle. You can e-mail him at [email protected], or call 206-624-2374.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.